News about "Glenmark Pharmaceuticals"

Glenmark Launches Calcium Gluconate Injection in US

Glenmark launches Calcium Gluconate Injection USP in the US, offering a bioequivalent and therapeutically equivalent alternative to Fresenius Kabi’s reference drug.

Glenmark Pharmaceuticals | 21/08/2026 | By News Bureau

Glenmark Pharmaceuticals Receives US FDA Approval for Fluticasone Propionate Nasal Spray

Glenmark Pharmaceuticals receives US Food and Drug Administration (FDA) approval for Fluticasone Propionate Nasal Spray, a bioequivalent and therapeutically equivalent generic of Flonase Nasal Spray.

Glenmark Pharmaceuticals | 20/08/2026 | By News Bureau

Glenmark Launches Generic Sugammadex Injection in US

Glenmark has launched generic Sugammadex Injection in the US, a bioequivalent and therapeutically equivalent version of Merck's BRIDION Injection.

Glenmark Pharmaceuticals | 29/07/2026 | By News Bureau

Glenmark Pharmaceuticals Launches Olanzapine for Injection 10 mg/vial Single-Dose Vial in US

Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection 10 mg/vial, a bioequivalent and therapeutically equivalent generic to Zyprexa IntraMuscular Injection.

Glenmark Pharmaceuticals | 06/07/2026 | By Akanki

Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.

Glenmark Pharmaceuticals | 04/07/2026 | By News Bureau |  126

Glenmark Pharma Receives Six Procedural Observations Following US FDA Inspection of Goa Facility

Glenmark Pharmaceuticals has received six procedural observations in a Form 483 following a US FDA GMP inspection of its Goa manufacturing facility. The company said there were no data integrity or repeat observations and expects no impact on the supply of its commercial products while it works with the regulator to address the findings.

Glenmark Pharmaceuticals | 02/07/2026 | By News Bureau |  536

Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer

Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.

Glenmark Pharmaceuticals | 02/07/2026 | By News Bureau

Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL

Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.

Glenmark Pharmaceuticals | 17/06/2026 | By News Bureau

Glenmark Launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), a bioequivalent and therapeutically equivalent generic version of Vimpat Injection.

Glenmark Pharmaceuticals | 05/06/2026 | By News Bureau

Glenmark Pharmaceuticals Launches Vancomycin for Injection USP in US

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP in the US market, expanding its injectable portfolio in a segment valued at nearly USD 37.9 million annually.

Glenmark Pharmaceuticals | 18/05/2026 | By News Bureau |  102